Downstream Processing: A Revalidation Study of Viral Clearance in the Purification of Monoclonal Antibody CB.Hep-1 - - BioPharm International


Downstream Processing: A Revalidation Study of Viral Clearance in the Purification of Monoclonal Antibody CB.Hep-1

To increase the inactivation factor of the whole sanitization procedure, the resistance of nonenveloped viruses HPV-2 and CPV was also studied in 0.1 N HCl (pH 1.0). The isoelectric pH of the purified poliovirus and CPV ranges from 5.5 to 7.0.24 This attribute will be drastically changed under the presence of the 0.1 N HCl allowing, in theory, a high virus inactivation factor. Results demonstrated this. HPV-2 was inactivated 6.13 Logs in 7 h and CPV was inactivated 6.60 Logs in just 1 h. Therefore, a robust sanitization protocol for the affinity chromatography step of a MAb CB.Hep-1 purification process should involve the combination of 70% ethanol and 0.1 N HCl in the studied exposure time.


A scale down of the MAb CB.Hep-1 purification process demonstrated removal factors of enveloped and nonenveloped model viruses similar to the first validation study. HSV-1, HIV-1, and CPV are sensitive to incubation with 70% ethanol (from 3.0 to 4.6 Logs). We find that 0.1 N HCl provides robust inactivation of more than 6.13 Logs of nonenveloped high resistance viruses. Ethanol at 20% concentration inactivated 3.7 Logs of enveloped viruses HSV-1 and HIV-1 but was totally ineffective in inactivating the nonenveloped viruses HPV-1 and CPV.


The authors kindly thank the Cuban National Center for Animal Breeding for producing and supplying the specific pathogen-free ascitic fluid used in this work.

Rodolfo Valdés is head of the monoclonal antibody production department at the Center for Genetic Engineering and Biotechnology (CGEB), Havana, Cuba, 537.2716022, ext. 7101,

María del Rosario Alemán is the head of the cell culture laboratory of the monoclonal antibody production department at CGEB.

Andrés Tamayo, Sigifredo Padilla, Lamay Dorta, and Biunayki Reyes are researchers at the monoclonal antibody production department at CGEB.

Enrique Noa, Marta Dubed, and Giselle Alvarez are researchers at the National Reference Center for AIDS Research, Havana, Cuba.

Déborah Geada and Leonor Navea is a researcher at the Research Institute of Tobacco, Department of Industrial Development, Havana, Cuba.

Tatiana González is an engineer at the Process Control Department of CGEB. Eutimio Gustavo Fernández is a researcher at Inorganic Chemistry Department, Center for Engineering and Chemical Researches, Havana, Cuba.


1. Quiñones Y, Agraz A, Silva A, Padrón G, Mella C, Díaz R, et al. High purity recombinant human alpha-2 interferon free from oligomeric forms in E. Coli. Highlights Modern Biochem 1989; 2:1237–1246.

2. Stum DC, Thienpont M, Collen D. Isolation y characterization of single chain urokinase (prourokinase) and urokinasa-inhibitor complex. J. Biological Chemistry 1986; 261:1267–1273.

3. Harbour C, Woodhouse G. Viral contamination of monoclonal antibody preparations: potential problems and possible solutions. Cytotechnology 1990; 4:3–12.

4. Hart CA. Transmissible spongioform encephalopathies. J Med Microbiol. 1995; 42:153–155.

5. Borovec S, Broumis C, Adcock W, Fang R, Uren E. Inactivation kinetics of model and relevant blood-borne viruses by treatment with sodium hydroxide and heat. Biologicals 1998; 26, 3:237–244.

6. Committee for Proprietary Medicinal Products. EEC regulatory document, note for guidance: Validation of viral removal and inactivation procedure. Biological, 1991; 19:247–25.

7. Darling JA, Spaltro JJ. Process validation for virus removal. Biopharm 1996; 10:42–50.

8. Minor P. Adventitious viral agents in biological product. Develop. Biol. Standard 1989; 70:173–179.

9. FDA. Guideline on general principles of process validation. CDER. Bethesda Md: 1978 May.

10. Juran JM, Gryna MF, editors Juran's quality control handbook, 4th ed. New York: McGraw-Hill; 1988.

11. Sofer G. Validation: ensuring the accuracy of scaled-down chromatography method. Biopharm 1998; 10:51–54.

12. Fontirrochi G, Dueñas M, Fernández E, Fuentes P, Pérez M, Mainet D, et al., A mouse hybridoma cell line secreting IgG and IgM with specificity for the Hepatitis B surface antigen virus requirements for biological substances. Biotecnología Aplicada 1993; 10:25–30.

13. Hardy E, Martínez E, Diago D, Díaz R, González D, Herrera L. Large scale production of recombinant Hepatitis B surface antigen from Pichia pastoris. J. Biotechnology 2000; 17:155–157.

14. Fernández ME, Díaz T, Galván A, Valdés R, González E, Ayala M, et al. Antigen recognition characteristics and comparative performance in immunoaffinity purification of two monoclonal antibodies specific for the Hepatitis B virus surface antigen. J Biotechnol. 1997; 56:69–80.

15. Valdés R, Ibarra N, Ruibal I, Bederraín A, Noa E, Herrera N, et al. Chromatographic removal combined with heat, acid and chaotropic inactivation of four model viruses. J. Biotechnology 2002; 96:251–258.

16. Valdés R, Díaz T, Nieto A, García C, Pérez M, García J, Quiñones Y. Sendai virus removal and inactivation during monoclonal antibody purification. Biotecnología Aplicada 2005; 12 (2):115–119.

17. Kelly DB, Jeening P, Wright R, Briaco C. Demonstrating the process robustness for chromatographic purification of a recombinant protein. Biopharm 1997; 10:36–45.

18. Berthold W, Walter J, Werz W. Experimental approaches to guarantee minimal risk of potential virus in purified monoclonal antibodies. Cytotechnology 1992; 9:189–201.

19. Laemmli. UK. Cleavage of structural proteins during the assembly by bacteriophage T 4. Nature 1970; 270:680–685.

20. Reed. LJ, Müench H. A simple method of estimating fifty per cent endpoints. Amer. J. Hyg. 1938; 27:493–487.

21. White EM, Grun BJ, Sur C-S, Sito FA. Process validation for virus removal and inactivation. BioPharm 1991; 4(5):30–33.

22. Willkommen H. Safety issue with recombinant technologies, assessment of clinical trial material. Bioprocess Int. Prague, 2006. Feb 21.

23. Cameron R, Davies J, Adcock W, Mac Gregor A, Bargord RJ, Cossart Y, Harcour C. The removal of model virus, poliovirus type 1 and canine parvovirus, during the purification of human albumin using ion-exchange chromatography procedures. Biologicals 1997; 25:391–401.

blog comments powered by Disqus



First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here